CCM
SLNO

Consonance Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Consonance Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-202,667
Closed -$7.63M – 44
2020
Q3 		$7.63M Hold
202,667
– – 0.93% 22
2020
Q2 		$6.75M Buy
+202,667
New +$8.78M 0.4% 29

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Consonance Capital Management's SLNO Position: Q4 2020 in Review

Consonance Capital Management sold out of Soleno Therapeutics (SLNO) in Q4 2020, closing a stake of 202,667 shares — an estimated $7.63M sold.

Consonance Capital Management first reported a position in SLNO in Q2 2020 and held it in 2 quarters. The position peaked at $7.63M in Q3 2020. 67 funds tracked by Wall St. Rank hold SLNO as of Q4 2020.

  • Consonance Capital Management reported no remaining Soleno Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Consonance Capital Management sold 202,667 Soleno Therapeutics shares in Q4 2020, an estimated $7.63M.
  • Consonance Capital Management first reported a position in Soleno Therapeutics in Q2 2020 and held it in 2 quarters.
  • Consonance Capital Management's Soleno Therapeutics position peaked at $7.63M in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2020.

Based on Consonance Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.